Roth Research Laboratory

Long-term benefit of SABR (stereotactic ablative radiation therapy) for operable early-stage NSCLC (non-small cell lung cancer) shown in a new study published in Lancet Oncology

https://www.sciencedirect.com/science/article/pii/S1470204521004010?casa_token=0FIuLMHFON4AAAAA:M5WfYQ5oY_cnSWajrRlBzkP7m4ov5uOn5Z4bFDoXtNm35GVK8a1WysGQglW6S__uoYmvhHh5kg